The methylation level of TFAP2A is a potential diagnostic biomarker for retinoblastoma: an analytical validation study.

Citation metadata

Date: Mar. 2, 2021
From: PeerJ(Vol. 9)
Publisher: PeerJ. Ltd.
Document Type: Report
Length: 5,051 words
Lexile Measure: 1330L

Document controls

Main content

Abstract :

Tumor-derived circulating tumor DNA (ctDNA) has demonstrated its excellent potential for cancer diagnosis by DNA methylome; therefore, this study aimed to identify the retinoblastoma (RB) specific methylated CpG loci as the RB diagnostic biomarkers and design a methylation specific assay to detect these biomarker from aqueous humor of RB patients. Through a genome-wide methylation profiling of tissue samples from patients with RB, normal retina and other retinal diseases, we shortlisted two CpG loci were only methylated in RB but not in normal retina or other retinal diseases. Both of these two CpG loci were located in the genome of TFAP2A. Through the screening, a primer and probe set for the two CpG loci were tested in fully methylated standards and RB tissues with a significant differentiation of RB. Our results of this assay tested in aqueous humor from RB revealed an accuracy of 92.7% for RB diagnosis. These results suggested our assay targeting the TFAP2A ctDNA methylation can be utilized for RB diagnosis and cancer monitoring.

Source Citation

Source Citation   

Gale Document Number: GALE|A653503945